Bruhn Claudia
Med Monatsschr Pharm. 2016 Jan;39(1):4-8.
The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, instead of an ACE inhibitor or an angiotensin-receptor blocker (ARB). In studies, sacubitril/ valsartan was superior to enalapril in reducing the risks of death and hospitalization for heart failure. Possible side effects of sacubitril/valsartan are hypotension, angioedema, impaired renal function and elevation in serum potassium levels. The drug should not be used in times of pregnancy and breast feeding, in patients with servere hepatic impairment (Child-Pugh C) and in combination with aliskiren in patients with diabetes.
沙库巴曲缬沙坦（诺欣妥）的分子组合是一种新型药物，用于降低慢性心力衰竭（纽约心脏协会II-IV级）且射血分数降低患者的心血管死亡风险和心力衰竭住院风险。它通常与其他心力衰竭治疗方法联合使用，而非替代血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂（ARB）。在研究中，沙库巴曲/缬沙坦在降低心力衰竭死亡和住院风险方面优于依那普利。沙库巴曲/缬沙坦可能的副作用包括低血压、血管性水肿、肾功能损害和血清钾水平升高。该药物不应在妊娠和哺乳期使用，严重肝功能损害（Child-Pugh C级）患者禁用，糖尿病患者不得与阿利吉仑联合使用。
